I am a
Home I AM A Search Login

Papers of the Week

Papers: 6 Aug 2022 - 12 Aug 2022

Pharmacology/Drug Development

2022 Aug 10

Curr Drug Metab

Pain Allaying Epalrestat-Loaded Lipid Nanoformulation for the Diabetic Neuropathic Pain Interventions: Design, Development and Animal Study.



Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus. Epalrestat, an aldose reductase inhibitor, has been approved for clinical therapy for diabetic peripheral neuropathic pain. In the present study, solid lipid-based nanoparticles are used for oral administration of epalrestat (E-SLN) and evaluated against diabetic neuropathic pain in a rat model.